|Articles|December 1, 2001
CMS expands coverage for verteporfin therapy
New York-The Centers for Medicare and Medicaid Services (CMS)-formerlythe Health Care Financing Administration-will begin reimbursing patientswho use verteporfin for injection (Visudyne) with occult choroidal neovascularization(CNV) lesions secondary to age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
2
Beyond The Walls: The “how and why” behind what drives today’s ophthalmologists
3
Q&A: Karolinne M. Rocha discusses the IOL and patient tolerance of residual astigmatism
4
Study identifies 6 key genes linking air pollution to dry eye disease
5














































.png)


